Any company hoping to make headway in the market for obesity therapies will need deep pockets, so it’s an encouraging sign that startup Metsera has launched with an impressive $290 million in financing.
Taking on established players like Novo Nordisk and Eli Lily will also need experienced leadership, and for that Metsera is drawing on the expertise of Clive Meanwell, former chief executive of The Medicines Company, who sold the company to Novartis for $9.7 billion.
